Go Pro
NASDAQ:LIMN

Liminatus Pharma Q1 2026 Earnings Report

Liminatus Pharma logo
$0.12 +0.01 (+13.04%)
As of 02:43 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Liminatus Pharma EPS Results

Actual EPS
-$0.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Liminatus Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Liminatus Pharma Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Liminatus Pharma Earnings Headlines

LIMN Share News Today
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel
Liminatus Pharma Inc. - Ordinary Shares - Class A
LIMN Liminatus Pharma, Inc.
See More Liminatus Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Liminatus Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Liminatus Pharma and other key companies, straight to your email.

About Liminatus Pharma

Liminatus Pharma (NASDAQ:LIMN), Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

View Liminatus Pharma Profile